Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 16/20 | 0.44 |
| ▸ | IDH2 | P48735 | 4/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395354 | 0.82 | NOTUM (0.58) | NOTUMIDH1IDH2GABRA1GABRG2 | |
| SCHEMBL15624402 | 0.82 | NOTUM (0.58) | NOTUMIDH1IDH2GABRA1GABRG2 | |
| SCHEMBL2458453 | 0.80 | CCR1 (0.41) | — | |
| SCHEMBL19806300 | 0.76 | PIM1 (0.34) | — | |
| SCHEMBL28054791 | 0.73 | BTK (0.34) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30936047 | 0.72 | IDH1 (0.39) | IDH1IDH2GABRA1GABRG2GABRB3 | |
| SCHEMBL20090323 | 0.72 | — | — | |
| SCHEMBL15326962 | 0.72 | CCR1 (0.64) | — | |
| SCHEMBL14655925 | 0.72 | JAK2 (0.41) | IDH1IDH2 | |
| SCHEMBL29590093 | 0.72 | CCR1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018017633-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | NOTUM 3998/4885IDH1 1950/4885IDH2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.